Great News for The CBD Enthusiasts as The Drug Maker GW Pharmaceuticals Will Soon Hold Patent On THC, CBD As Brain Cancer Cures.
GW Pharmaceuticals, a drug company that specializes in cannabis-based pharmaceuticals, has received early approval on a patent covering the use of marijuana chemicals for treating brain cancer.
GW Pharmaceuticals announced Wednesday that it has been issued a Notice of Allowance from the U.S. Patent Office for a patent application involving the use of THC and CBD, the two main chemicals in marijuana, for treating gliomas.
Once a patent application is deemed a genuine invention, the Patent Office sends a Notice of Allowance that outlines the fees involved with final approval.
Specifically, the company provides this description of the patent:
“The subject patent specifically covers a method for treating glioma in a human using a combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) wherein the cannabinoids are in a ratio of from 1:1 to 1:20 (THC:CBD) with the intent to reduce cell viability, inhibit cell growth or reduce tumor volume.”
Filed in 2009, GW’s patent application lists Otsuka Pharmaceutical as a collaborator and initially claimed the invention of the “use of a combination of cannabinoids in the manufacture of a medicament for use in the treatment of cancer.”
Related: What is CBD and is it legal?
However, it’s likely that the application was revised since then to be more specific in its claims, including the ratio of THC to CBD used and the type of cancer treated.
Indeed, the use of cannabis and cannabis-derived chemicals to fight a wide range of cancers has long been suggested by pre-clinical research as well as anecdotal reports.
On the other hand, the first clinical trial to investigate these cancer treatments only began last month, launched by GW Pharmaceuticals for their cannabis drug Sativex.
The trial investigates Sativex in combination with the standard chemotherapy drug temozolomide and involves 20 patients with recurrent glioblastoma multiforme (GBM), an aggressive and rare form of brain cancer.
GW Pharmaceuticals also announced in November that it had begun human trials of a CBD-rich cannabis drug for the treatment of pediatric epilepsy.
GW Pharmaceuticals has assembled a large, talented in-house team of world-leading professionals with expertise spanning botanical growing, pre-clinical and clinical R&D, product development, manufacturing, and testing.
As a world leader in cannabis plant medicine, GW Pharmaceuticals understand that they have an important role to play in informing and shaping the external environment to realize the full medical potential of the cannabis plant while considering patient safety and the protection of public health.
Not sure what is CBD? Not a problem, we have put together a beginner’s guide to CBD.